D. DeAngelo

发表

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

E. Estey, D. Gilliland, D. Gilliland, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias.

J. Aster, L. Silverman, W. Stock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

K. Gregory, Hema M Sundar, M. Deininger, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2014 .

Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop

J. Radich, G. Martinelli, R. V. van Etten, 2011, American journal of hematology.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE

M. Liedtke, H. Kantarjian, E. Jabbour, 2018, Cancer.

Targeting oncogenic interleukin‐7 receptor signalling with N‐acetylcysteine in T cell acute lymphoblastic leukaemia

A. Look, S. Sallan, Sarah Daakour, 2015, British journal of haematology.

Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia

J. Temel, T. Graubert, K. Ballen, 2015, Cancer.

PhALLCON Soars to New Heights-Faster, Stronger, but Better?

D. DeAngelo, Rebecca P Bystrom, Jacqueline S Garcia, 2024, Journal of the American Medical Association (JAMA).

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

R. Houot, A. Logan, M. Bishop, 2023, Journal for ImmunoTherapy of Cancer.

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

R. Houot, A. Logan, M. Bishop, 2022, Journal of hematology & oncology.

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

J. Dipersio, G. Rosti, J. Cortes, 2022, American journal of hematology.

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

H. Kantarjian, G. Rosti, C. Chuah, 2024, Leukemia.

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

G. Rosti, C. Chuah, M. Talpaz, 2023, HemaSphere.

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

T. Graubert, C. Corless, T. George, 2010 .

The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols

D. Neuberg, S. Sallan, L. Silverman, 2011, British journal of haematology.

Targeting MTH FD 2 in acute myeloid leukemia

Stone, Kung, K. Stegmaier, 2016 .

Prediction of risk for myeloid malignancy in clonal hematopoiesis.

D. Neuberg, B. Ebert, W. Wong, 2022, NEJM evidence.

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

K. Bhalla, D. DeAngelo, T. Fischer, 2008 .